Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Inc ($ARQT) announced an update on their ongoing clinical study. Arcutis Backs New Itch Study in Atopic Dermatitis. This Ph...

Arcutis Targets Real-World Itch Relief Data With New Phase 4 Roflumilast Study

Arcutis Biotherapeutics Inc (($ARQT)) has held its Q2 earnings call. Read on for the main highlights of the call. Arcutis Biotherapeutics’ latest e...

Arcutis Biotherapeutics Earnings Call Highlights Growth Momentum

Arcutis Biotherapeutics ( ($ARQT) ) has issued an update. Arcutis Biotherapeutics reported strong second-quarter 2026 results, underscoring the mom...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARQT	$25.64	-2.10%	731.85K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARQT	$25.64	-2.1%	731.85K
3
4
5
6

ARQT

Get Arcutis Biotherapeutics, Inc. Data in Excel

Get Arcutis Biotherapeutics, Inc. Data in Excel